Hemodynamic action of captopril in coronary patients with heart failure tolerant to nitroglycerin

Clin Cardiol. 1997 Dec;20(12):999-1004. doi: 10.1002/clc.4960201205.

Abstract

Background: At present there is little dispute that clinical tolerance of organic nitrates occurs during long-term treatment of patients with stable angina pectoris and congestive heart failure.

Hypothesis: Captopril exerts a favorable hemodynamic effect in coronary patients with heart failure who are clinically tolerant to nitroglycerin.

Methods: Development of nitrate tolerance was observed during intravenous nitroglycerin treatment (10 mg/h) in 16 of 19 patients (7 women, 12 men; mean age 56 +/- 8 years) with coronary heart disease [stenosis > or = 75%, New York Heart Association (NYHA) classes II-III). The criterion applied was a loss of efficacy of at least 50% with regard to mean pulmonary capillary wedge pressure compared with the maximum effect of nitrate. The effect of captopril (50 mg p.o.) was determined in a blank test. Captopril (50 mg p.o.) was administered again at the stage of clinically manifest nitrate tolerance.

Results: Compared with the effect of captopril alone, significantly more pronounced reductions in mean pulmonary capillary wedge pressure (33% compared with 27%) and in mean pulmonary arterial pressure (36% compared with 17%) and significantly greater increases in cardiac index (14% compared with 7%) and stroke work index (34% compared with 18%) (p < 0.05 in each case; Wilcoxon test for linked random samples) were measured. Maintaining nitroglycerin infusion, the effect of captopril (at least 90% of the maximum effect) lasted for 123 +/- 24 min. The baseline values (at least 75% decline in the effect of captopril) were only reached after 369 +/- 34 min.

Conclusion: The results document a favorable hemodynamic effect of captopril in nitrate tolerance which is significantly better than that of captopril alone.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Captopril / administration & dosage
  • Captopril / adverse effects
  • Captopril / therapeutic use*
  • Coronary Disease / complications
  • Coronary Disease / drug therapy
  • Coronary Disease / physiopathology*
  • Drug Administration Routes
  • Drug Therapy, Combination
  • Female
  • Heart Failure / complications
  • Heart Failure / drug therapy
  • Heart Failure / physiopathology*
  • Hemodynamics / drug effects
  • Humans
  • Male
  • Middle Aged
  • Nitroglycerin / administration & dosage
  • Nitroglycerin / adverse effects
  • Nitroglycerin / therapeutic use*
  • Reproducibility of Results
  • Safety
  • Treatment Outcome
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / therapeutic use*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Vasodilator Agents
  • Captopril
  • Nitroglycerin